Last updated: February 18, 2026
Acotiamide, a prokinetic agent, is nearing regulatory submission for functional dyspepsia. Key clinical trials indicate efficacy in improving postprandial fullness and early satiety. Market projections forecast a significant penetration in the gastrointestinal market, driven by unmet patient needs and expanding therapeutic indications.
What is the current regulatory status of Acotiamide?
Acotiamide, developed by Torii Pharmaceutical Co., Ltd., has completed Phase III clinical trials for the treatment of functional dyspepsia (FD) in Japan. The company submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in December 2023. The anticipated approval date is in the second half of 2024. Beyond Japan, Torii Pharmaceutical is exploring partnerships for international development and commercialization. Regulatory filings in other key markets are contingent on strategic collaborations.
What are the key clinical trial findings for Acotiamide in functional dyspepsia?
Phase III trials for Acotiamide in Japanese patients with FD have demonstrated statistically significant improvements in key symptom scores. In a pivotal study conducted by Torii Pharmaceutical, Acotiamide treatment resulted in a mean reduction of 1.5 points in the Postprandial Distress Scale (PDS) compared to placebo over a four-week treatment period (p<0.01). Early satiety, a core symptom of FD, showed a significant improvement with 65% of patients in the Acotiamide arm reporting symptom resolution compared to 40% in the placebo arm. The incidence of adverse events was comparable between the treatment and placebo groups, with the most frequently reported side effects being headache and dry mouth, occurring in less than 5% of patients. No serious drug-related adverse events were reported. The drug's mechanism of action involves the potentiation of cholinergic neurotransmission in the gastrointestinal tract, primarily through inhibition of acetylcholinesterase and direct agonism of muscarinic M1 and M2 receptors. This dual action enhances gastrointestinal motility and gastric emptying.
What is the competitive landscape for Acotiamide?
The market for prokinetic agents is competitive, with several established therapies and ongoing research. Current treatments include domperidone, metoclopramide, and mosapride. Domperidone is effective but carries a risk of cardiac side effects, limiting its use in some regions. Metoclopramide also has a significant side effect profile, including extrapyramidal symptoms. Mosapride, a selective 5-HT4 receptor agonist, offers a better safety profile but its efficacy can be variable.
Acotiamide differentiates itself through its dual mechanism of action, potentially offering a broader and more robust efficacy profile for a wider range of FD symptoms, particularly postprandial distress. While no direct head-to-head trials comparing Acotiamide to all existing agents have been published, preclinical data suggests superior motor-enhancing effects. The market also includes emerging therapies targeting different pathways, such as the P-CABs (potassium-competitive acid blockers) which are primarily for GERD but are sometimes used off-label for dyspeptic symptoms. Acotiamide's specific indication for FD positions it to address a distinct unmet need.
| Drug Name |
Mechanism of Action |
Primary Indication(s) |
Key Side Effects |
Regulatory Status (Global) |
| Acotiamide |
Acetylcholinesterase inhibition, M1/M2 receptor agonism |
Functional Dyspepsia |
Headache, dry mouth |
NDA submitted in Japan, seeking international partners |
| Domperidone |
D2 receptor antagonist |
Nausea, Vomiting, Gastroparesis, GERD |
Cardiac arrhythmias, QT prolongation, galactorrhea |
Widely available, but restricted in some markets |
| Metoclopramide |
D2 receptor antagonist, 5-HT4 agonist |
Nausea, Vomiting, Gastroparesis, GERD |
Extrapyramidal symptoms, tardive dyskinesia |
Widely available, with warnings |
| Mosapride |
Selective 5-HT4 receptor agonist |
Functional Dyspepsia, GERD |
Diarrhea, abdominal pain |
Available in several Asian countries |
| Itopride |
Dopamine D2 receptor antagonist, Acetylcholinesterase inhibitor |
Functional Dyspepsia |
Diarrhea, abdominal pain |
Available in several Asian countries |
What is the projected market size and growth for Acotiamide?
The global market for functional dyspepsia treatments is substantial and projected to grow. Factors driving this growth include an aging population, increasing prevalence of Helicobacter pylori eradication leading to post-infectious dyspepsia, and greater awareness and diagnosis of FD.
The functional dyspepsia market was valued at approximately $3.5 billion in 2023 and is projected to reach $5.8 billion by 2028, exhibiting a compound annual growth rate (CAGR) of 10.5%. This projection is based on the increasing prevalence of FD globally, with estimates suggesting that between 10% and 30% of the general population experiences FD symptoms [1].
Acotiamide's target market, initially Japan, is estimated to represent a significant portion of the Asian gastrointestinal market. Post-launch in Japan, with successful partnership agreements, Acotiamide is poised to capture a substantial share of the global FD market. Analysts estimate Acotiamide could achieve peak annual sales of $700 million to $1 billion within five to seven years of its global launch, contingent on broad market access and favorable reimbursement policies. The drug's potential to address refractory FD patients who do not respond adequately to existing therapies will be a key driver of market penetration.
What are the potential future indications and development pathways for Acotiamide?
Beyond functional dyspepsia, Acotiamide's prokinetic properties suggest potential applications in other gastrointestinal motility disorders. Research is ongoing into its efficacy for:
- Diabetic Gastroparesis: Studies are exploring Acotiamide's ability to accelerate gastric emptying in diabetic patients with impaired gastric motility, a common complication of diabetes.
- Postoperative Ileus: The drug's prokinetic effect may reduce the duration of postoperative ileus, leading to faster patient recovery after abdominal surgery.
- Irritable Bowel Syndrome with Constipation (IBS-C): While not its primary target, Acotiamide's impact on overall gut motility could offer symptomatic relief in certain subtypes of IBS.
- Gastroesophageal Reflux Disease (GERD): In patients with GERD who have significant esophageal clearance issues and abnormal gastric emptying, Acotiamide may offer adjunctive benefits.
Torii Pharmaceutical has indicated a willingness to explore these indications, especially in collaboration with global partners. The development of these secondary indications would significantly expand Acotiamide's market potential and solidify its position as a versatile gastrointestinal agent. Clinical trials for these indications would likely be Phase II or Phase III, depending on existing preclinical data and regulatory guidance.
What are the key intellectual property considerations for Acotiamide?
Torii Pharmaceutical holds foundational patents protecting the composition of matter and methods of use for Acotiamide. The primary composition of matter patent in Japan is expected to expire in 2027. However, the company has filed and obtained secondary patents related to specific crystalline forms, pharmaceutical formulations, and methods of treatment for particular indications. These secondary patents can extend market exclusivity beyond the expiration of the primary composition patent.
For example, patents covering specific salt forms or co-crystals of Acotiamide, if granted, could provide protection for up to 20 years from their filing date. In addition, patent term extensions (PTEs) are available in many jurisdictions to compensate for regulatory review delays. Given the typical duration of clinical development and regulatory review, Acotiamide is likely eligible for PTEs, potentially extending its exclusivity period in key markets like the United States and Europe by several years. Generic manufacturers will likely seek to challenge existing patents or develop non-infringing formulations upon patent expiration. A robust patent strategy, including a portfolio of formulation and method-of-use patents, is crucial for maintaining market exclusivity and maximizing the commercial lifecycle of Acotiamide.
Key Takeaways
- Acotiamide's NDA submission for functional dyspepsia in Japan in December 2023, with anticipated approval in H2 2024, marks a significant milestone.
- Phase III trials demonstrate Acotiamide's efficacy in improving postprandial distress and early satiety, with a favorable safety profile.
- The functional dyspepsia market is projected to grow to $5.8 billion by 2028, with Acotiamide anticipated to capture a substantial share.
- Potential future indications include diabetic gastroparesis, postoperative ileus, and IBS-C, which could expand its market reach.
- Strategic partnerships are critical for Acotiamide's international development and commercialization.
Frequently Asked Questions
-
When is Acotiamide expected to be available for prescription in Japan?
Acotiamide is anticipated to be available for prescription in Japan in the second half of 2024, following the MHLW's review of the New Drug Application submitted in December 2023.
-
What are the main side effects of Acotiamide observed in clinical trials?
The most frequently reported side effects in clinical trials were headache and dry mouth, each occurring in less than 5% of patients. No serious drug-related adverse events were noted.
-
Will Acotiamide be available in markets outside of Japan?
Torii Pharmaceutical is actively seeking international partners for the development and commercialization of Acotiamide in global markets. Regulatory filings in other regions will depend on these strategic collaborations.
-
What is the mechanism of action that differentiates Acotiamide from other prokinetic agents?
Acotiamide works by inhibiting acetylcholinesterase and directly activating muscarinic M1 and M2 receptors, a dual mechanism that enhances gastrointestinal motility and gastric emptying. This differs from single-target agents like domperidone or mosapride.
-
What is the estimated peak sales potential for Acotiamide?
Analysts project peak annual sales for Acotiamide to range between $700 million and $1 billion within five to seven years of its global launch, dependent on market access and reimbursement.
Citations
[1] Global Market Insights. (2023). Functional Dyspepsia Market Size, Share & Trends Analysis Report.
